Abstract
The present invention relates to a method of inhibiting or reducing the proliferation of prostate cancer cells, such as androgen independent prostate cancer (AIPC) cells, the method comprising administering to the cells a PLA2 inhibitor. In one embodiment the PLA2 inhibitor is a conformationally constrained molecule derived from a peptide consisting essentially of amino acid residues 70-74 of a human sPLA2-IIA protein, or the equivalent residues in other sPLA2 proteins.
| Original language | English |
|---|---|
| Patent number | WO/2004/064822 A1 |
| Priority date | 7/06/02 |
| Filing date | 10/06/03 |
| Publication status | Published - 2024 |
